Clark Estates Inc. NY Acquires Shares of 42,000 Lantheus Holdings, Inc. $LNTH

Clark Estates Inc. NY acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 42,000 shares of the medical equipment provider’s stock, valued at approximately $2,154,000. Clark Estates Inc. NY owned approximately 0.06% of Lantheus as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Stanley Laman Group Ltd. raised its position in Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after purchasing an additional 22,229 shares during the period. American Assets Inc. bought a new position in shares of Lantheus during the 3rd quarter valued at approximately $872,000. Campbell & CO Investment Adviser LLC purchased a new stake in Lantheus during the 3rd quarter valued at $2,184,000. Assetmark Inc. lifted its position in Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after buying an additional 19,844 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Lantheus during the second quarter worth $654,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Up 0.9%

LNTH stock opened at $73.87 on Monday. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The firm’s 50-day moving average is $67.24 and its 200 day moving average is $59.55. The company has a market capitalization of $4.90 billion, a PE ratio of 31.04 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Truist Financial increased their target price on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Mizuho boosted their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.